



PAPER

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Org. Biomol. Chem.*, 2024, 22, 4326**PIDA-promoted metal-free [3 + 2] heteroannulation of β -ketothioamides with 4-hydroxy coumarins: chemo-/regioselective access to furo[3,2-c]chromen-4-ones at room temperature†**Anup Kumar Yadav, Dhananjay Yadav, Vipin Kumar, Subhasish Ray  and Maya Shankar Singh *

Herein, we report a viable protocol to access furo[3,2-c]chromen-4-ones by engaging easily accessible 4-hydroxy coumarins as a three-atom CCO unit and thioamides as a C2 coupling partner, mediated by phenyliodine(III) diacetate (PIDA) at room temperature in a highly efficient and pot-/step-economical manner. This strategy not only avoids potential toxicity and tiresome workup conditions, but also features operational simplicity, a broad substrate scope, good functional group tolerance, high yields, easy scalability and exclusive selectivity. A mechanistic study has shown that this metal-free reaction is triggered by PIDA *via* activation of the β -carbon of 4-hydroxy coumarin, followed by a nucleophilic addition/intramolecular cyclization/dethiohydration cascade. High-resolution mass spectra (HRMS) study confirms the key intermediates involved during the course of the reaction, elucidating the reaction pathways, and demonstrates the excellent regio- and chemoselectivity of this approach.

Received 18th March 2024,
Accepted 27th April 2024DOI: 10.1039/d4ob00438h
rsc.li/obc**Introduction**

Synthesis of fused heterocyclic motifs has always been an important task in organic synthesis, owing to their diverse range of properties, such as aromaticity, rigidity and electron delocalization, which make them ideal candidates for the development of therapeutic agents. Coumarins and their fused analogues represent a class of important heterocycles that have made outstanding contributions in the prevention and treatment of disease.¹ Three-substituted coumarins and their derivatives have attracted a certain amount of attention due to their wide scope of pharmacological properties.² Owing to their remarkable biological significance, the search for new bioactive coumarins is still of immense interest to scientists to reveal their medical applications. Hence, several approaches for functionalization of coumarins to achieve novel analogues with new biological properties have been described.^{3,4} Coumarin motifs are frequently found in many natural products and biologically active intermediates.⁵ In the scientific community, there is a growing interest in coumarin motifs due to their anti-HIV, antioxidant, antifungal, antihelminthic and


antibacterial properties.⁶ Moreover, they are commonly used in the food and cosmetic industries as additives and are also found to act as insecticides, optical brighteners and as fluorescent and laser dyes.⁷

A remarkable growth in hypervalent iodine-mediated transformation, as stoichiometric reagents as well as catalysts, has been well documented due to their excellent properties, such as mildness, ease of handling, good selectivity, environmental friendliness and high stability in the presence of atmospheric oxygen and moisture.⁸ The peculiar reactivity of hypervalent iodine reagents arises from the 3-center–4-electron bond (3c–4e), or hypervalent bond, which is longer, more polarized and weaker than a standard covalent bond, leading to higher electrophilic reactivity.⁹ In recent years, efforts have focused on cyclic hypervalent iodine reagents due to their higher stability.¹⁰ Moreover, confinement of the oxygen lone pairs out of the 3c–4e plane disfavours reductive elimination between the axial ligands.¹¹ Over the past few years, hypervalent iodine reagents have emerged as efficient organocatalysts for oxidative transformation of a wide range of organic substrates.¹²

The development of new synthetic approaches to furo-fused chromen-4-ones is an important research area of organic synthesis. Various methods have been developed for the synthesis of furo[3,2-c]coumarin motifs, employing coupling and cyclization reactions involving suitable precursors.¹³ Mosslemin *et al.*^{14a} reported a one-pot three-component reaction of 4-hydroxy coumarin with aldehydes and isocyanides

Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, India. E-mail: mssingh@bhu.ac.in

†Electronic supplementary information (ESI) available. CCDC 2298668 and 2298674. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d4ob00438h>



Scheme 1 Previous reports and this work.

(Scheme 1a). Phan and co-workers^{14b} coupled 4-hydroxy coumarin with ketones in the presence of iodine to synthesize furo-fused coumarins (Scheme 1b). Vagh *et al.*^{14c} reported an acyl transfer reaction of suitable starting material in the presence of acyl halides and base to construct furo-fused coumarin motifs (Scheme 1c). Although these reported methods are useful tools to access furo[3,2-*c*]coumarins, most of them suffer from significant limitations, such as the use of specific substrates and harsh conditions. Hence, it is highly desirable to explore a sustainable and efficient general strategy to construct furo[3,2-*c*]coumarins, especially those containing amino and aroyl groups, which can be further functionalized. Our careful literature survey revealed that 4-hydroxycoumarin and β -ketothioamide have not been explored as coupling partners for the synthesis of furo[3,2-*c*]coumarins. Recently, we devised a cascade metal-/catalyst-free strategy to construct furo-fused quinoxalines from β -ketothioamide and quinoxalin-2-ones at room temperature.¹⁵ To this end, our continuing efforts to synthesize diverse heterocycles¹⁶ prompted us to develop more innovative and sustainable methods for newer analogues. Herein, we report a convenient metal-free one-pot strategy to synthesize furo[3,2-*c*]coumarins employing 4-hydroxy coumarin and β -ketothioamide at room temperature (Scheme 1d).

Results and discussion

The efficient and selective synthesis of fused heterocyclic systems *via* cascade reactions remains an important pursuit in synthetic organic chemistry. Synthons containing both electrophilic and nucleophilic sites (ambiphilic synthons) have great potential in developing new reaction pathways. One such synthon are β -ketothioamides (KTAs), which have proven to be

a versatile class of strategic precursors due to their intrinsic synthetic tunability with fitting partners in a chemo- and regio-selective manner, for the construction of various heterocycles.¹⁷ Due to our constant efforts to develop new protocols towards heterocyclic frameworks utilizing KTA as a synthon,¹⁸ we envisioned further expanding their synthetic repertoire by reacting them with 4-hydroxy coumarin as a coupling partner. Herein, we report the synthesis of furo[3,2-*c*]coumarins from 4-hydroxy coumarins and β -ketothioamides *via* an intermolecular cross-coupling and intramolecular cyclization strategy mediated by the eco-friendly hypervalent iodine reagent phenyliodine(III) diacetate (PIDA), at room temperature under open air, in a highly efficient, rapid and pot-/step-economical manner (Scheme 1d). The reactions were completed within 10 minutes and the pure products were isolated in good yield.

4-Hydroxycoumarin (**1a**) and β -ketothioamide (**2a**) were selected as test substrates to optimize the reaction conditions. Initially, the reaction of **1a** (0.30 mmol) and **2a** (0.25 mmol) in 2 mL of toluene at room temperature in an open atmosphere was carried out without any reagent. The reaction did not proceed at all, and the starting materials remained completely unreacted, even after 24 h (Table 1, entry 1). In an effort to trigger the reaction, this test reaction was performed in the presence of iodine, which enabled the formation of product in a trace amount after 1 h (Table 1, entry 2). The above result encouraged us to continue our investigations to obtain efficient condition for the formation of product in good yield.

Next, we used phenyliodine(III) diacetate (0.2 equiv.) instead of iodine, and the product was obtained in 10% isolated yield

Table 1 Optimization of reaction conditions^a

Entry	Reagent (equiv.)	Solvent (mL)	Time	Yield ^b (%)
1	None	Toluene	24 h	NR
2	I ₂ (1.5)	Toluene	60 min	Trace
3	PIDA (0.2)	Toluene	30 min	10
4	PIDA (1.0)	Toluene	30 min	43
5	PIDA (1.5)	Toluene	10 min	64
6	PIDA (2.0)	Toluene	10 min	64
7	PIDA (1.5)	Benzene	10 min	58
8	PIDA (1.5)	CCl ₄	10 min	50
9	PIDA (1.5)	CHCl ₃	10 min	45
10	PIDA (1.5)	DCM	10 min	30
11	PIDA (1.5)	DMF	10 min	40
12	PIDA (1.5)	DCE	10 min	52
13	PIFA (1.5)	Toluene	10 min	60
14	NIS (1.5)	Toluene	10 min	NR
15	ZnCl ₂ (1.5)	Toluene	10 min	NR
16	Yb(OTf) ₃ (0.5)	Toluene	10 min	NR

^a Reaction conditions: **1a** (0.3 mmol), **2a** (0.25 mmol), and solvent (2.0 mL), room temperature in an open atmosphere. ^b Isolated yield. PIDA = phenyliodine(III) diacetate; PIFA = phenyliodine(III) bis(trifluoroacetate); NIS = *N*-iodosuccinimide.


after 30 min (Table 1, entry 3). With PIDA as a good promoter in hand, next we planned to optimize its loading, and it was found that the use of 1.5 equiv. of PIDA provided the best results (Table 1, entries 4–6). In order to achieve better efficiency, the model reaction was also assessed by varying reaction medium. Thus, the test reaction was performed in several non-polar and polar aprotic solvents, such as benzene, tetrachloromethane, chloroform, dichloromethane, dimethylformamide and dichloroethane, but none of them provided better results than toluene (Table 1, entries 7–12). After optimizing toluene as the choice of solvent, we screened other promoters, such as PIFA (bis(trifluoroacetoxy)iodobenzene), NIS (*N*-iodosuccinimide), ZnCl_2 and $\text{Yb}(\text{OTf})_3$ (Table 1, entries 13–16). Of these only PIFA triggered the reaction, providing the product in good yield (Table 1, entry 13). Thus, the best yield, cleanest reaction and most facile workup were achieved employing **1a** (0.30 mmol), **2a** (0.25 mmol) and PIDA (1.5 equiv.) in 2.0 mL of toluene at room temperature in an open atmosphere (Table 1, entry 5).

With the optimized conditions to hand, to delineate this approach, the scope and generality of this protocol was next examined by employing a broad range of β -ketothioamides and substituted 4-hydroxy coumarins. Notably, a wide range of β -ketothioamides bearing an R^1 moiety as phenyl and aryl groups substituted with both electron-donating (Me, Et, OMe, methylenedioxy) as well as electron-withdrawing (F, Cl, Br, CF_3) substituents, irrespective of their *ortho*-, *meta*- and *para*-positions and substitution pattern, were well tolerated, affording the products in moderate to good yield (Table 2, **3a–3l**). It was noteworthy that the strong electron-withdrawing groups, such as trifluoromethyl and 3,4,5-trifluorobenzene, were also tolerated well and gave the desired products in good yield (Table 2, **3m–3o**). After successful coupling of thioamides bearing the R^1 moiety as diverse aryl groups, the R^1 moiety as heteroaromatics, such as pyridyl and thienyl, were also tolerated well, furnishing the product in 50% and 65% yield, respectively (Table 2, **3p, 3q**).

Notably, thioamides bearing not only aromatic and heteroaromatic groups at the R^1 moiety, but also extended aromatics, such as naphthyl and biphenyl, were also found to be compatible, affording the products in good yields (Table 2, **3r, 3s**). In order to gain further insight into this transformation and to show the versatility of this protocol, thioamides containing an R^1 moiety as aliphatic substituents, such as cyclopropyl and iso-butyl, were also used and found to be tolerated well, giving the desired products in good yield (Table 2, **3t, 3u**).

To expand the range of substrates for this reaction, the applicability of thioamides bearing different substituents at the R^2 moiety was also investigated under standard conditions. The reaction proceeded well, with thioamides bearing the R^2 moiety as 4-methylphenyl and 3-bromophenyl furnishing the desired products in good yield (Table 2, **3v, 3w**). This protocol has also been found to be compatible with random variation in the moieties R^1 and R^2 , resulting in the corresponding products in high yields (Table 2, **3x–3z**). Next, we turned our attention to evaluating the scope of substituted coumarins.

Table 2 Scope of furo[3,2-*c*]coumarins **3**



7-Methyl and 6-chloro-coumarins also displayed good reactivity for this transformation, furnishing the corresponding products (Table 2, **3za–3zd**) in 62–74% yields.


Furthermore, to check the practical efficacy of this protocol, we performed a large-scale reaction employing 4-hydroxy coumarin **1a** (9.6 mmol, 1.55 g) and β -ketothioamide **2a** (8 mmol, 2.04 g) in the presence of PIDA (12 mmol, 3.86 g) under opti-

mized reaction conditions (Scheme 2). The desired product **3a** was obtained in 61% yield (1.86 g), which was found to be comparable to the small-scale reaction. This observation indicated that this method could be easily implemented for large-scale preparation of furo[3,2-*c*] coumarins.


The structures of all the newly synthesized furo[3,2-*c*]coumarins **3** were fully characterized by their satisfactory spectral (^1H , $^{13}\text{C}\{^1\text{H}\}$ NMR and HRMS) studies. The mass spectra of these compounds displayed molecular ion peaks at the appropriate *m/z* values. Further structures of two representative compounds **3a** and **3d** were unambiguously established by single-crystal X-ray diffraction analysis (Table 2; see ESI for more details, Fig. S1 and S2†).

To devise a probable mechanism, we also carried out some control experiments using a simple coumarin moiety (**1'**) with β -ketothioamide (**2a**) under the standard reaction conditions (Scheme 3, eqn (1)). The reaction did not proceed at all and the starting materials remained unconsumed, indicating that the hydroxy group is necessary for the transformation to occur. Next, we performed the reaction of **1a** with **2a** in the presence of the radical scavenger BHT (butylated hydroxytoluene) (3.0 equiv.) to understand the reaction pathway. Workup of the reaction provided the desired product **3a** exclusively, suggesting that the reaction does not involve the radical pathway (Scheme 3, eqn (2)).


Taking into consideration all these reaction outcomes, a plausible pathway for this PIDA-initiated cascade sequence enabling the formation of compounds **3** is depicted in Scheme 4. Initially, PIDA reacts with the 3-position of 4-hydroxy coumarin, increasing its electrophilicity to form intermediate **A**, which subsequently undergoes nucleophilic



Scheme 2 Gram-scale synthesis of **3a**. Reaction conditions: **1a** (0.3 mmol), **2a** (0.25 mmol), PIDA (12 mmol) and solvent (2.0 mL), room temperature in an open atmosphere.



Scheme 3 Control experiment. Reaction conditions: **1a** (0.3 mmol), **2a** (0.25 mmol), PIDA (1.5 equiv.), BHT (3 equiv.) and solvent (2.0 mL), room temperature in an open atmosphere.



Scheme 4 Plausible reaction mechanism.

attack by the α -carbon of thioamide to generate intermediate **B**, eliminating PhI and AcOH. Intermediates **A** and **B** have both been detected by HRMS analysis (see ESI for details, Fig. S3 and S4†). Intermediate **B** probably undergoes intra-molecular *O*- or *S*-cyclization *via* path I or path II, to give intermediates **C** and **D**, respectively. Next, intermediate **C** suffers desulfurization to furnish the desired furo[3,2-*c*]coumarin **3**. Generation of H_2S as the only by-product makes this process highly attractive¹⁹ (detected by the lead acetate test). The alternative path II, for intermediate **B**, could also be possible, enabling the formation of thiophene-fused coumarin **4** *via* intermediate **D**, which was not observed, even in a trace, during our observations, with only coumarin **3** being obtained exclusively, suggesting *O*-cyclization through path I, and making the protocol highly chemo- and regioselective.

Conclusions

In conclusion, we have successfully synthesized diverse furo[3,2-*c*]coumarins in moderate to good yields featuring excellent chemo- and regioselectivity under mild conditions. The unique structure of the furo-fused coumarin ring not only imparts unique chemical reactivity, but also the ability to interact with various biological targets, which makes them attractive candidates for the development of novel therapeutic agents. Moreover, to the best of our knowledge, direct inter-molecular cross-coupling employing β -ketothioamide to access furo[3,2-*c*]coumarin has not been described so far. The simple operating module at room temperature, metal-free conditions, protecting group-free, easy workup and gram scalability not only make this cascade strategy very promising for academic research and medicinal applications but also broadens the

application of β -ketothioamides. Furo[3,2-*c*] coumarins are highly significant motifs in natural products and pharmaceutical applications. We anticipate that this approach will be useful for providing a valuable source of new physiologically active coumarin agents.

Experimental

General information

The commercially available solvents and reagents were used as received without any further purification. The β -ketothioamides (2) were synthesized by the reported procedure.²⁰ Toluene was purchased from Merck. PIDA and coumarins were purchased from Sigma Aldrich. All the reactions were monitored by analytical thin layer chromatography (TLC) using Merck pre-coated aluminium sheets, and visualized by a UV lamp. Flash column chromatography was performed on silica gel (230–400 mesh). The ^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra were recorded on a JEOL 500 FT-NMR spectrometer operating at 500 and 125 MHz, respectively. Chemical shifts (δ) for ^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR are given in parts per million (ppm) using the residual solvent peaks as a reference relative to tetramethylsilane (TMS). Coupling constant (J) values are reported in hertz (Hz). High-resolution mass spectra (HRMS, m/z) were recorded in EI or ESI mode, on a Sciex X500R QTOF instrument. All the reactions were carried out using a single-neck round-bottom (25 mL) borosilicate flask. Melting points were determined with a Büchi B-540 melting point apparatus and are uncorrected. IUPAC names were obtained using the ChemDraw (version 19.1) software.

General procedure for the synthesis of compounds 3

4-Hydroxy coumarins **1** (0.3 mmol), β -ketothioamides **2** (0.25 mmol) and PIDA (1.5 equiv.) were added into a 25 mL oven-dried, single-neck, round-bottom flask, followed by addition of 2.0 mL of toluene. The reaction mixture was stirred at room temperature for 10 min in an open atmosphere. After completion of the reaction (monitored by TLC), the reaction was quenched with water (10 mL), followed by extraction with ethyl acetate (15 mL) and water (2×10 mL). The combined organic layer was dried over anhydrous Na_2SO_4 and the solvent was evaporated under reduced pressure. The crude residue thus obtained was purified by silica gel flash column chromatography to give the pure products **3** (20:1 hexane/ethyl acetate). The isolated product was dried under vacuum and then the analytical studies were performed.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We gratefully acknowledge the financial support from the Science and Engineering Research Board (CRG/2023/000021),

IoE Incentive grants, BHU (Scheme No. 6031) and JC Bose National Fellowship (JCB/2020/000023), New Delhi. The authors (AKY, DY, VK and SR) are thankful to UGC, New Delhi for fellowships. We also acknowledge the support of DST-FIST for basic and high-end analytical facilities for the department.

References

- (a) C. Kontogiorgis, A. Detsi and D. Hadjipavlou-Litina, *Expert Opin. Ther. Pat.*, 2012, **22**, 437–454; (b) K. N. Venugopala, V. Rashmi and B. Odhav, *BioMed. Res. Int.*, 2013, **2013**, 1–14; (c) D. Yu, M. Suzuki, L. Xie, S. L. Morris-Natschke and K. H. Lee, *Med. Res. Rev.*, 2003, **23**, 322–345.
- (a) M. Musa, J. Cooperwood and M. O. Khan, *Curr. Med. Chem.*, 2008, **15**, 2664–2679; (b) A. Kathuria, S. Jalal, R. Tiwari, A. Nasrolahi-Shirazi, S. Gupta, S. Kumar, K. Parang and S. K. Sharma, *Chem. Biol. Interfaces*, 2011, **1**, 279–296; (c) G. Hertrampf, K. Kusserow, S. Vojnovic, A. Pavic, J. I. Müller, J. Nikodinovic-Runic and T. A. M. Gulder, *Chem. – Eur. J.*, 2022, **28**, e202200394.
- (a) M. Golshani, M. Khoobi, N. Jalalimanesh, F. Jafarpour and A. Ariaifard, *Chem. Commun.*, 2017, **53**, 10676–10679; (b) B. Niu, W. Zhao, Y. Ding, Z. Bian, C. U. Pittman, A. Zhou and H. Ge, *J. Org. Chem.*, 2015, **80**, 7251–7257; (c) F. Jafarpour, M. Darvishmolla, N. Azaddoost and F. Mohaghegh, *New J. Chem.*, 2019, **43**, 9328–9332; (d) H. Stefani, K. Gueogjan, F. Manarin, S. Farsky, J. Zukerman-Schpector, I. Caracelli, S. Pizano Rodrigues, M. Muscará, S. Teixeira, J. Santin, I. Machado, S. Bolonheis, R. Curi and M. Vinolo, *Eur. J. Med. Chem.*, 2012, **58**, 117–127; (e) M. Kumar, T. Kaur, V. K. Gupta and A. Sharma, *RSC Adv.*, 2015, **5**, 17087–17095.
- (a) M. Gupta, P. Kumar, V. Bahadur, K. Kumar, V. S. Parmar and B. K. Singh, *Eur. J. Med. Chem.*, 2018, **2018**, 896–900; (b) D. Kang, K. Ahn and S. Hong, *Asian J. Org. Chem.*, 2018, **7**, 1136–1150; (c) M. Min, Y. Kim and S. Hong, *Chem. Commun.*, 2013, **49**, 196–198; (d) X. H. Cao, X. Pan, P. J. Zhou, J. P. Zou and O. T. Asekun, *Chem. Commun.*, 2014, **50**, 3359–3362.
- (a) *Biology, Applications, and Mode of Action*, ed. R. O’Kennedy and R. D. Thornes, John Wiley & Sons, Chichester, New York, 1997; (b) *Advances in Structure and Activity Relationship of Coumarin Derivatives*, ed. S. Penta, Academic Press, 2015; (c) Q. Yang, R. Guo and J. Wang, *Asian J. Org. Chem.*, 2019, **8**, 1742–1765; (d) L. Wu, X. Wang, W. Xu, F. Farzaneh and R. Xu, *Curr. Med. Chem.*, 2009, **16**, 4236–4260; (e) R. D. H. Murray, J. Mendey and S. A. Brown, *The Natural Coumarins*, Wiley, New York, 1982.
- (a) L. Huang, X. Yuan, D. Yu, K. H. Lee and C. H. Chen, *Virology*, 2005, **332**, 623–628; (b) F. Borges, F. Roleira, N. Milhazes, L. Santana and E. Uriarte, *Curr. Med. Chem.*, 2005, **12**, 887–916; (c) H. A. El-Wahab, M. A. El-Fattah, N. A. El-Khalik, H. S. Nassar and M. M. Abdelall, *Prog. Org. Coat.*, 2014, **77**, 1506–1511; (d) G. Zhao, C. Peng, W. Du and

- S. Wang, *Fitoterapia*, 2013, **89**, 250–256; (e) T. Smyth, V. N. Ramachandran and W. F. Smyth, *Int. J. Antimicrob. Agents*, 2009, **33**, 421–426; (f) O. Galayev, Y. Garazd, M. Garazd and R. Lesyk, *Eur. J. Med. Chem.*, 2015, **105**, 171–181; (g) N. Renuka and K. A. Kumar, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 6406–6409; (h) M. Z. Zhang, R. R. Zhang, J. Q. Wang, X. Yu, Y. L. Zhang, Q. Q. Wang and W. H. Zhang, *Eur. J. Med. Chem.*, 2016, **124**, 10–16; (i) Y. Lu, D. Hu, S. Ma, X. Zhao, S. Wang, G. Wei, X. Wang, A. Wen and J. Wang, *Int. Immunopharmacol.*, 2016, **34**, 44–52; (j) Y. G. Peng and L. Zhang, *J. Dermatol. Treat.*, 2019, **30**, 389–395.
- 7 (a) S. M. Razavi, H. Nazemiyeh, A. Delazar, R. Hajiboland, M. M. Rahman, S. Gibbons, L. Nahar and S. D. Sarker, *Phytochem. Lett.*, 2008, **1**, 159–162; (b) N. Z. Ballin and A. T. Sørensen, *Food Control*, 2014, **38**, 198–203; (c) A. Fischer, C. Cremer and E. H. Stelzer, *Appl. Opt.*, 1995, **34**, 1989–2003; (d) G. Cravotto, G. M. Nano, G. Palmisano and S. Tagliapietra, *Tetrahedron: Asymmetry*, 2001, **12**, 707–709; (e) R. Pratap and V. J. Ram, *Chem. Rev.*, 2014, **114**, 10476–10526; (f) S. Sandhu, Y. Bansal, O. Silakari and G. Bansal, *Bioorg. Med. Chem.*, 2014, **22**, 3806–3814; (g) M. Zahradink, *The Production and Application of Fluorescent Brightening Agents*, Wiley, New York, 1992; (h) M. Maeda, *Laser Dyes*, Academic Press, New York, 1984.
- 8 (a) R. D. Richardson and T. Wirth, *Angew. Chem., Int. Ed.*, 2006, **45**, 4402–4404; (b) M. Ochiai and K. Miyamoto, *Eur. J. Org. Chem.*, 2008, 4429–4239; (c) M. Uyanik and K. Ishihara, *Chem. Commun.*, 2009, 2086–2099; (d) M. S. Yusubov and V. V. Zhdankin, *Mendeleev Commun.*, 2010, **20**, 185–191; (e) F. V. Singh and T. Wirth, *Chem. – Asian J.*, 2014, **9**, 950–971.
- 9 (a) J. I. Musher, *Angew. Chem., Int. Ed. Engl.*, 1969, **8**, 54–68; (b) J. C. Martin, *Science*, 1983, **221**, 509–514; (c) E. Le Du and J. Waser, *Chem. Commun.*, 2023, **59**, 1589–1604.
- 10 (a) Y. Li, D. P. Hari, M. V. Vita and J. Waser, *Angew. Chem., Int. Ed.*, 2016, **55**, 4436–4454; (b) R. L. Amey and J. C. Martin, *J. Org. Chem.*, 1979, **44**, 1779–1784.
- 11 T.-Y. Sun, X. Wang, H. Geng, Y. Xie, Y.-D. Wu, X. Zhang and H. F. Schaefer III, *Chem. Commun.*, 2016, **52**, 5371–5374.
- 12 (a) V. V. Zhdankin, *Hypervalent Iodine Chemistry: Preparation, Structure and Synthetic*, Wiley, Chichester, vol. I, 2013; (b) T. Dohia and Y. Kita, *Chem. Commun.*, 2009, 2073–2085; (c) F. V. Singh and T. Wirth, *Chem. – Asian J.*, 2014, **9**, 950; (d) R. Narayan, S. Manna and A. P. Antonchick, *Synlett*, 2015, **26**, 1785–1803; (e) A. Maity and D. C. Powers, *Synlett*, 2019, **30**, 257–262; (f) F. V. Singh, S. E. Shetgaonkar, M. Krishnan and T. Wirth, *Chem. Soc. Rev.*, 2022, **51**, 8102–8139.
- 13 (a) L. Santana, E. Uriarte, F. Roleira, N. Milhazes and F. Borges, *Curr. Med. Chem.*, 2004, **11**, 3239–3261; (b) X. Zhu, X. P. Xu, C. Sun, T. Chen, Z. L. Shen and S. J. Ji, *Tetrahedron*, 2011, **67**, 6375–6381; (c) M. Adib, M. Mahdavi, S. Bagherzadeh and H. R. Bijanzadeh, *Synlett*, 2009, 2542–2544; (d) M. Kumar, S. Bagchi and A. Sharma, *RSC Adv.*, 2015, **5**, 53592–53603; (e) N. Kerru, L. Gummidi, K. K. Gangu, S. Maddila and S. B. Jonnalagadda, *ChemistrySelect*, 2020, **5**, 4104–4110; (f) R. Lei, W. Lan, M. Li, Z. Qin and B. Fu, *Tetrahedron Lett.*, 2023, **128**, 154697; (g) S. Battula, P. Kothuri, H. Bhumannagaria and K. Nayani, *Org. Biomol. Chem.*, 2024, **22**, 1671–1675; (h) L. Chen, Y. Li and M.-H. Xu, *Org. Biomol. Chem.*, 2010, **8**, 3073–3077; (i) S. M. Rajesh, S. Perumal, J. C. Menendez, S. Pandian and R. Murugesan, *Tetrahedron*, 2012, **68**, 5631–5636.
- 14 (a) M. H. Mosslemin, M. Anary-Abbasinejad, A. F. Nia, S. Bakhtiari and H. Anaraki-Ardakani, *J. Chem. Res.*, 2009, **2009**, 599–601; (b) P. H. Pham, Q. T. Nguyen, N. K. Tran, V. H. Nguyen, S. H. Doan, H. Q. Ha, T. Truong and N. T. Phan, *Eur. J. Org. Chem.*, 2018, 4431–4435; (c) S. S. Vagh, B. J. Hou, A. Edukondalu, P. C. Wang and W. Lin, *Org. Lett.*, 2021, **23**, 842–846.
- 15 S. Ray, V. Kumar, S. Singh, K. Bandyopadhyay, S. Saha and M. S. Singh, *Adv. Synth. Catal.*, 2024, **366**, 262–268.
- 16 (a) P. Pali and M. S. Singh, *Org. Lett.*, 2023, **25**, 2258–2263; (b) A. K. Yadav, V. Kumar, P. Pali, S. Ray, A. Verma and M. S. Singh, *Adv. Synth. Catal.*, 2023, **365**, 2943–2948; (c) G. Shukla, K. Raghuvanshi and M. S. Singh, *J. Org. Chem.*, 2022, **87**, 13935–13944; (d) S. Ray, S. Singh, G. Kumar, G. Shukla and M. S. Singh, *Adv. Synth. Catal.*, 2022, **364**, 3204–3210; (e) S. Soni, G. Shukla and M. S. Singh, *Org. Biomol. Chem.*, 2022, **20**, 6784–6798.
- 17 (a) C. H. Ding, J. L. Dong, L. S. H. Yu and J. W. Xie, *Chin. Chem. Lett.*, 2018, **29**, 517–520; (b) L. Wen, N. Wang, W. Du, M. Zhu, C. Pan, L. Zhang and M. Li, *Chin. J. Chem.*, 2021, **39**, 1831–1837; (c) J. Zheng, H. Gu, Q. Chen and W. Yang, *Org. Biomol. Chem.*, 2023, **21**, 2069–2080; (d) M. Li, X. J. Kong and L. R. Wen, *J. Org. Chem.*, 2015, **80**, 11999–12005; (e) H. Lu, C. Y. Tan, H. X. Zhang, J. L. Zhang, J. Y. Liu, H. Y. Li and P. F. Xu, *J. Org. Chem.*, 2018, **83**, 15245–15255; (f) X. Zhang, C. Liu, Y. Deng and S. Cao, *Org. Biomol. Chem.*, 2020, **18**, 7540–7544; (g) Q. Zeng, X. Huang, M. Liu, Z. Yu and Y. Xiao, *Org. Lett.*, 2022, **24**, 8186–8191.
- 18 (a) M. A. Ansari, D. Yadav, S. Soni, A. Srivastava and M. S. Singh, *J. Org. Chem.*, 2019, **84**, 5404–5412; (b) M. A. Ansari, D. Yadav, S. Soni and M. S. Singh, *Org. Biomol. Chem.*, 2019, **17**, 9151–9162; (c) M. A. Ansari, D. Yadav and M. S. Singh, *Chem. – Eur. J.*, 2020, **26**, 8083–8089; (d) P. Pali, G. Shukla, P. Saha and M. S. Singh, *Org. Lett.*, 2021, **23**, 3809–3813; (e) G. Shukla, P. Saha, P. Pali, K. Raghuvanshi and M. S. Singh, *J. Org. Chem.*, 2021, **86**, 18004–18016; (f) P. Pali, D. Yadav, S. C. Sahoo and M. S. Singh, *J. Org. Chem.*, 2022, **87**, 12342–11235; (g) S. Singh, G. Shukla, S. Ray and M. S. Singh, *Synthesis*, 2023, **55**, 1893–1903; (h) S. Khan, M. A. Ansari and M. S. Singh, *Org. Lett.*, 2023, **25**, 642–646; (i) G. Kumar, M. A. Ansari and M. S. Singh, *Tetrahedron*, 2023, **142**, 133542; (j) D. Yadav and M. S. Singh, *Eur. J. Org. Chem.*, 2023, e202201335.
- 19 T. Ausma and L. J. De Kok, *Front. Plant Sci.*, 2019, **10**, 1–10.
- 20 X. M. Zeng, C. Y. Meng, J. X. Bao, D. C. Xu, J. W. Xie and W. D. Zhu, *J. Org. Chem.*, 2015, **80**, 11521–11528.